An interventional study of NeuraGen 3D Nerve Guide Matrix in Digital Nerve Injury, sponsored by Integra LifeSciences Corporation. Terminated at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Integra LifeSciences Corporation · Not applicable, Interventional, and Treatment
This is a 10-subject, 12-month follow-up, prospective, multi-center, open-label, single arm clinical trial designed to understand the initial performance characteristics and confirm the safety profile of the NeuraGen 3D Nerve Guide Matrix.
The NeuraGen® 3D Nerve Guide Matrix is indicated for the repair of peripheral nerve discontinuities where tension-free closure can be achieved by flexion of the digit or extremity.
Integra LifeSciences Corporation is the lead sponsor of 81 studies on the registry; 5 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Exclusion Criteria:
Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
Device: NeuraGen 3D Nerve Guide Matrix
Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
The primary objective of this study is to evaluate return to sensory recovery with the NeuraGen 3D Nerve Guide Matrix in a small group of subjects with primary nerve injury of the hand.(s2PD) at each post-operative timepoint of the study.
To be assessed during in office visits using the DeMayo 2-point discrimination device
Time frame: 12 Months
Moving 2 Point Discrimination Test (m2PD) at each post-operative timepoint of the study:
To be assessed during in office visits using the DeMayo 2-point discrimination device
Time frame: 12 Months
Grip Strength Test at each post-operative timepoint of the study
To be assessed during in office visits using the Camry hand dynamometer
Time frame: 12 Months
Pinch Strength Test at each post-operative timepoint of the study
To be assessed during in office visits using the Baseline Digital Pinch Gauge
Time frame: 12 Months
Semmes-Weinstein Monofilament Testing at each post-operative timepoint of the study
To be assessed during in office visits using the Baseline Tactile Semmes-Weinstein monofilament
Time frame: 12 Months
Disabilities of the Arm, Shoulder and Hand (DASH) Score at each post-operative timepoint of the study
To be completed via in office visits
Time frame: 12 Months
Michigan Hand Outcomes Questionnaire (MHQ) at each post-operative timepoint of the study
To be completed via in office visits
Time frame: 12 Months
Continuous Visual Analog Scale for Pain at each post-operative timepoint of the study
0-100 Scale, 0-no pain at all, 100- worst possible pain. To be completed via in office visits
Time frame: 12 Months
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Integra LifeSciences Corporation